These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment Initiation. Gonzalez CJ; Kapadia SN; Niederdeppe J; Dharia A; Talal AH; Lloyd AR; Franco R; Labossiere S; Shapiro MF; Wethington E J Gen Intern Med; 2024 Sep; 39(12):2268-2276. PubMed ID: 38782810 [TBL] [Abstract][Full Text] [Related]
23. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service. Phillips C; Schulkind J; O'Sullivan M; Edelman N; Smith HE; Verma S; Jones CJ J Viral Hepat; 2020 Feb; 27(2):176-187. PubMed ID: 31566851 [TBL] [Abstract][Full Text] [Related]
24. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs. Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457 [TBL] [Abstract][Full Text] [Related]
25. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. Austin EJ; Tsui JI; Barry MP; Tung E; Glick SN; Ninburg M; Williams EC J Subst Abuse Treat; 2022 Jun; 137():108684. PubMed ID: 34911656 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, Canada. Thompson KA; Blank G; Toy J; Moore DM; Lachowsky N; Bacani N; Zhang W; Sereda P; Lima VD; Barrios R; Montaner JSG; Hull MW Liver Int; 2022 Jul; 42(7):1528-1535. PubMed ID: 35274805 [TBL] [Abstract][Full Text] [Related]
27. Applying core theory and spatial analysis to identify hepatitis C virus infection "core areas" in British Columbia, Canada. Butt ZA; Mak S; Gesink D; Gilbert M; Wong J; Yu A; Wong S; Alvarez M; Chong M; Buxton J; Tyndall M; Krajden M; Janjua NZ J Viral Hepat; 2019 Mar; 26(3):373-383. PubMed ID: 30447122 [TBL] [Abstract][Full Text] [Related]
28. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators. Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548 [TBL] [Abstract][Full Text] [Related]
29. Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis. Levander XA; Vega TA; Seaman A; Korthuis PT; Englander H Subst Abus; 2022; 43(1):245-252. PubMed ID: 34161198 [No Abstract] [Full Text] [Related]
30. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Ward KM; McCormick SD; Sulkowski M; Latkin C; Chander G; Falade-Nwulia O Int J Drug Policy; 2021 Feb; 88():103019. PubMed ID: 33160152 [TBL] [Abstract][Full Text] [Related]
31. Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. Harris M; Guy D; Picchio CA; White TM; Rhodes T; Lazarus JV Int J Drug Policy; 2021 Oct; 96():103320. PubMed ID: 34261587 [TBL] [Abstract][Full Text] [Related]
32. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Reed JR; Jordan AE; Perlman DC; Smith DJ; Hagan H Syst Rev; 2016 Jul; 5(1):110. PubMed ID: 27401499 [TBL] [Abstract][Full Text] [Related]
33. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol. Busolo D; Woodgate R JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011 [TBL] [Abstract][Full Text] [Related]
34. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. Ti L; Socías ME; Wood E; Milloy MJ; Nosova E; DeBeck K; Kerr T; Hayashi K PLoS One; 2018; 13(3):e0194162. PubMed ID: 29579073 [TBL] [Abstract][Full Text] [Related]
35. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study. Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883 [TBL] [Abstract][Full Text] [Related]
36. Training the healthcare workforce: the global experience with telementorship for hepatitis B and hepatitis C. Corcorran MA; Thornton K; Struminger B; Easterbrook P; Scott JD BMC Health Serv Res; 2023 Aug; 23(1):824. PubMed ID: 37533025 [TBL] [Abstract][Full Text] [Related]
37. Implementing a new HCV model of care for people who use drugs. Herranz Mochales A; Picchio CA; Nicolàs A; Macià MD; Fernández-Baca MV; Serrano J; Bonet L; Trelles M; Sansó A; Rubí AR; Zamora A; García-Gasalla M; Buti M; Vilella À; Lazarus JV JHEP Rep; 2024 Oct; 6(10):101145. PubMed ID: 39308984 [TBL] [Abstract][Full Text] [Related]
38. Innovative Approaches to Engaging Homeless and Marginally Housed Patients in Care: a Case Study of Hepatitis C. Conti J; Dryden E; Fincke BG; Dunlap S; McInnes DK J Gen Intern Med; 2023 Jan; 38(1):156-164. PubMed ID: 35879538 [TBL] [Abstract][Full Text] [Related]
39. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846 [TBL] [Abstract][Full Text] [Related]
40. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study. Marshall AD; Martinello M; Treloar C; Matthews GV Int J Drug Policy; 2022 Nov; 109():103828. PubMed ID: 35994937 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]